It is the newest electrode in Cochlear’s portfolio of implantable hearing solutions
“This approval underscores Cochlear’s design philosophy, which is to take the very best of what we’ve learned from each generation of electrode and apply it to improve the next,” said Chris Smith, president of Cochlear Americas, in the release. “The addition of the Nucleus CI422, the world’s thinnest, full length electrode, to our comprehensive portfolio is a strong testament to our ongoing collaboration with surgeons and clinicians to help meet the individual needs of patients.”
Cochlear Americas is headquartered in Centennial, Colo.
Related Articles on FDA Approvals:
Mevion Medical Systems Receives FDA 510(k) Clearance for Proton Therapy System
Hansen Medical Receives FDA 510(k) Clearance for Peripheral Vascular Interventions System
Medicrea Receives FDA Clearance for the LigaPASS Spinal Fixation System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.